logo
Book a meeting
Vyriad

Vyriad

Biotechnology, 2900 37th Street 110 Nw BLDG, Rochester, Minnesota, 55901, United States, 51-200 Employees

vyriad.com

  • facebook
  • twitter
  • instagram
  • LinkedIn

phone no Phone Number: 50********

Who is VYRIAD

At Vyriad, we are developing the next generation of targeted genetic therapies by engineering viruses, viral vectors and viral envelope glycoproteins to deliver genes directly to targeted...

Read More

lock icon Get Full Access
map
  • 2900 37th Street 110 Nw BLDG, Rochester, Minnesota, 55901, United States Headquarters: 2900 37th Street 110 Nw BLDG, Rochester, Minnesota, 55901, United States
  • 2015 Date Founded: 2015
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $10 Million to $25 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from VYRIAD

email-formate-icon
View Email Formats for Vyriad
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding Vyriad

Answer: Vyriad's headquarters are located at 2900 37th Street 110 Nw BLDG, Rochester, Minnesota, 55901, United States

Answer: Vyriad's phone number is 50********

Answer: Vyriad's official website is https://vyriad.com

Answer: Vyriad's revenue is $10 Million to $25 Million

Answer: Vyriad's SIC: 2834

Answer: Vyriad's NAICS: 325412

Answer: Vyriad has 51-200 employees

Answer: Vyriad is in Biotechnology

Answer: Vyriad contact info: Phone number: 50******** Website: https://vyriad.com

Answer: At Vyriad, we are developing the next generation of targeted genetic therapies by engineering viruses, viral vectors and viral envelope glycoproteins to deliver genes directly to targeted cells. This targeting technology facilitates oncolytic virotherapy, in vivo gene therapies and gene editing applications. We are testing our oncolytic viruses as monotherapies and in combination with immuno-oncology drugs. Phase 1-2 Clinical Studies are currently active in: Non-small cell lung cancer Squamous cell carcinoma of the head and neck Metastatic colorectal cancer Breast cancer Bladder cancer Other cancer types Vyriad has clinical research collaboration agreements with Regeneron, Mayo Clinic, and other leading research and medical institutions.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access